A Phase 3, Multicenter, Open-Label 156-Week Extension Study To Evaluate The Long-Term Safety And Tolerability Of Oral Atogepant For The Prevention Of Migraine In Participants With Chronic Or Episodic Migraine
Latest Information Update: 24 Oct 2025
At a glance
- Drugs Atogepant (Primary)
- Indications Migraine; Migraine with aura; Migraine without aura
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors AbbVie; Allergan
Most Recent Events
- 21 Oct 2025 Status changed from active, no longer recruiting to completed.
- 16 Apr 2024 Planned End Date changed from 13 Sep 2024 to 8 Oct 2025.
- 16 Apr 2024 Planned primary completion date changed from 13 Sep 2024 to 8 Oct 2025.